

c.stim[®]

**DRY EYE
TREATMENT**



ELEGANT DESIGN FOR EASE OF USE



INTERFACE

Large HD screen
Easy to use
Intuitive interface



HANDPIECE

Ergonomic shape
Tip adapted to the facial area
Precise treatment
Easy to clean



DESIGN

Compact
Elegant
Robust



TROLLEY

Ergonomic
Multiple storage areas
Mobile on castors

STATE-OF-THE-ART TECHNOLOGY WITH CLINICAL BENEFITS

Safe and effective treatment with Stim-ULI™ technology

Our C.Stim® revolutionary IPL relying on our unique Stim-ULI™ (Uniform Light Intensity) technique offers the best combination of clinical efficacy and patient comfort.




Single handpiece with integrated water-based cooling system:

- Improved patient comfort
- Applies a thin layer of gel during treatment
- Delivers the same energy level from first to last shot
- Optimal preservation of flash lamp life: 30,000 shots/3,750 sessions

Regulated pulse train for safety and effectiveness

- Respects the skin's thermal relaxation time (TRT)
- No thermal damage to the skin
- No inflammatory reaction
- Controlled energy accumulation for better results



Safe and effective treatment for phototypes 1 to 5

- Light spectrum of 610 nm to 1,200 nm is less absorbed by melanin
- Energy controlled by pulse train, limiting increase in tissue temperature
- Stim-ULI™ technology for a perfectly homogeneous energy distribution




TREATMENT: A FAST, SIMPLE PROTOCOL

- 1 **SESSION** in less than 10 minutes
- 2 **WEEKS** between sessions
- 3 **SESSIONS** for complete treatment
- 4 **SHOTS** per side




DURING TREATMENT



4 SHOTS ON THE LOWER PERI-ORBITAL AREA

AFTER TREATMENT



FOR OPTIMAL RESULTS: MANUAL MEIBUM EXPRESSION, MADE EASIER BY THE HEAT FROM C.Stim I.P.L.

ADDED VALUE FOR CLINICAL PRACTICE

PRACTITIONER

- Multi-action treatment offer
- Fast, simple treatment
- Combination treatments for long-term results
- Optimisation of post-surgical outcome when used before surgery (refractive, cataract)
- Improved patient compliance with topical glaucoma treatment
- Contact lenses can be worn for longer
- No consumables

PATIENT

- Safe, effective, long-lasting treatment
- Better quality of life
- Comfortable treatment
- No disruption to social life
- Reduction in symptoms from the first session
- Neuropathic pain relief
- Improved contact lens comfort
- Patient satisfaction after refractive and cataract surgery
- Improved tolerance of topical glaucoma treatments


**TREAT
THE ROOT
CAUSES:**



**MULTIPLE MECHANISMS
OF ACTION WITH C.Stim
I.P.L. THERAPY:**

1

M.G.D.
Meibomian Gland Dysfunction



SPEED UP MEIBOMIAN GLAND AND LACRIMAL GLAND METABOLISM by stimulating the parasympathetic nervous system [1,2,3,4,5,6]

2


INFLAMMATION



LIQUEFY MEIBUM FOR MEIBOMIAN GLAND EXPRESSION using the heat generated by I.P.L. [7]

3

DEMODEX



STOP THE VICIOUS CYCLE OF CHRONIC INFLAMMATION by coagulating new blood vessels and reducing inflammatory agents [8,9,10,11]




DECREASE DEMODEX through coagulation and necrosis of the pigmented exoskeleton [9,12,13]

+

**MULTIPLE
CLINICAL
RESULTS:**

- Improved tear film quality [14,15,21]
- Better meibum quality and expression [16,17]
- Reduction in patient symptoms [17]
- Neuropathic pain relief [18]
- Reduced inflammatory markers (cytokines) in tears [19,20]





TECHNICAL SPECIFICATIONS

GENERAL INFORMATION

Technology	I.P.L. (Intense Pulsed Light)
Wavelength	610 – 1,200 nm
Fluence	1 to 14 J/cm ²
Spot size	18 x 45 mm
Stim-ULI™ technology	Uniform Light Intensity Unique technology for a perfectly homogeneous energy distribution (FR patent pending)
Dimensions	540 (H) x 320 (W) x 380 (D) mm
Weight	25 kg
Filter	610 nm, anti-UVA, UVB and UVC filter
Cooling system	Water
Flash lamp	Xenon lamp
Power supply	110/230 VAC, 50/60 Hz
Operating temperature	15 – 35 °C
Treatment duration	3 to 4 sessions
Accessories	Operator protective glasses, patient protective goggles
Marking	CE medical, class IIb

*Specifications are subject to change without notice. Non contractual pictures.
©2021. C.Stim® is a registered trademark of Quantel Medical and Lumibird Medical. All rights reserved.*

BIBLIOGRAPHY

1. Parasympathetic Innervation of the Meibomian Glands in Rats – Mark S. LeDoux et al. – Investigative Ophthalmology & Visual Science, October 2001, Vol. 42, No. 11.
2. Characterization of the innervation of the meibomian glands in humans, rats and mice – Bründl, M. et al. Annals of Anatomy (2021), Vol. 233.
3. Neurotransmitter Influence on Human Meibomian Gland Epithelial Cells – Wendy R. Kam and David A. Sullivan – Investigative Ophthalmology & Visual Science, November 2011, Vol. 52, No. 12.
4. The Dopaminergic Neuronal System Regulates the Inflammatory Status of Mouse Lacrimal Glands in Dry Eye Disease – Ji, Yong Woo et al. Investigative Ophthalmology & Visual Science (2021), Vol. 62.
5. TFOS DEWS II Pathophysiology Report – Anthony J. Bron, et al. – The Ocular Surface, 2017, p 441 to 515.
6. The neurobiology of the meibomian glands – Cox SM, Nichols JJ – Ocular Surface, July 2014.
7. Multicenter Study of Intense Pulsed Light Therapy for Patients with Refractory Meibomian Gland Dysfunction – Reiko Arita, et al. – Cornea Volume 37, Number 12, December 2018.
8. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition – Yu Ri Woo, et al. International Journal of Molecular Sciences, September 2016.
9. Rosacea: Epidemiology, pathogenesis, and treatment – Barbara M. Rainer et al. – DERMATO-ENDOCRINOLOGY 2018, VOL. 9, NO. 1, e1361574 (10 pages).
10. Treatment of ocular rosacea – Edward Wladis et al. – Survey of Ophthalmology (2018), Vol. 63.
11. Improved telangiectasia and reduced recurrence rate of rosacea after treatment with 540 nm-wavelength intense pulsed light: A prospective randomized controlled trial with a 2-year follow-up – Luo, Y. et al. – Experimental and Therapeutic Medicine (2020), Vol. 19.
12. Therapeutic Effect of Intense Pulsed Light on Ocular Demodicosis – Zhang, X., et al. – Current Eye Research 2019, Vol. 3.
13. Intense Pulsed Light Therapy for Patients with Meibomian Gland Dysfunction and Ocular Demodex Infestation – Cheng et al. – Current Medical Sciences (2019), Vol. 39.
14. Long-term effects of intense pulsed light treatment on the ocular surface in patients with rosacea-associated meibomian gland dysfunction – Seo Kyoung Yul et al. – Contact Lens and Anterior Eye (2018), Vol. 41.
15. TFOS DEWS II Tear Film Report – Willcox Mark et al. – The Ocular Surface (2017), Vol. 15.
16. Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction – Vigo, L. et al. – Journal of Visualized Experiment (2019), N° 146.
17. Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines – Choi, M. et al. – Scientific Reports (2019), Vol. 9.
18. TFOS DEWS II Pain and Sensation Report – Belmonte Carlos, et al. – The Ocular Surface (2017), Vol. 15.
19. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction – LIU, R et al. – American Journal of Ophthalmology (2017).
20. Effect of inflammation on lacrimal gland function – Driss Zoukhri – Experimental Eye Research, May 2006; 82(5): 885–898.
21. Aqueous deficiency is a contributor to evaporation-related dry eye disease – Charles W. McMonnies – Eye and Vision (2020) 7:6.

Patient information:
www.mydryeyedisease.com



Manufacturer

Quantel Medical
1 Rue du Bois Joli – CS40015
63808 Cournon d'Auvergne – FRANCE
Tel.: +33 (0)4 73 745 745
Email: contact@lumibirdmedical.com
ISO 13485 : 2016

Headquarters

Lumibird Medical
1 Rue du Bois Joli – CS40015
63808 Cournon d'Auvergne – FRANCE
Tel.: +33 (0)4 73 745 745

QUANTEL MEDICAL

A brand of



LUMIBIRD
MEDICAL

www.lumibirdmedical.com